Lamisil (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, preventing the synthesis of ergosterol, an essential component of fungal cell membranes. The resulting buildup of squalene and loss of ergosterol compromise the fungal cell structure, leading to cell death while sparing human cells.

The specific dose and frequency of Lamisil are determined by the prescribing healthcare professional based on the infection type, severity, patient age, and treatment guidelines. Patients should follow the prescriber’s instructions and the product label for optimal results.

Safety data for topical terbinafine during pregnancy or lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil.

To place an order, submit an enquiry on the Lamisil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisil belongs to the allylamine class, which acts on a different fungal pathway than azole antifungals (e.g., clotrimazole). Allylamines often achieve faster fungal clearance and are effective against dermatophytes resistant to some azoles, making Lamisil a valuable alternative for certain skin infections.

Store Lamisil at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and excessive heat. Ensure the container is tightly closed when not in use to maintain stability.

Apply a thin layer of the cream or gel to the affected skin area once or twice daily, as directed by the prescriber. Gently rub it in until fully absorbed, and wash hands before and after application to avoid accidental contact with eyes or mucous membranes.

While uncommon, serious adverse reactions can include severe contact dermatitis, allergic swelling or hives, Stevens‑Johnson syndrome, and systemic effects such as liver enzyme elevation if significant absorption occurs. Patients should stop use and seek medical attention if they notice any severe or unexpected symptoms.

Lamisil should not be used on broken, inflamed or infected skin, on mucous membranes, or by individuals with a known hypersensitivity to terbinafine or any component of the formulation. Patients with severe liver disease should also avoid use unless specifically advised by a physician.